About: Metastatic melanoma treatment with checkpoint inhibitors in the COVID‐19 era: experience from an Italian Skin Cancer Unit

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Metastatic melanoma treatment with checkpoint inhibitors in the COVID‐19 era: experience from an Italian Skin Cancer Unit Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Metastatic melanoma treatment with checkpoint inhibitors in the COVID‐19 era: experience from an Italian Skin Cancer Unit
Creator	Agostini, A Agostini, Andrea Brizio, M Brizio, Matteo Fava, Paolo Fava, P Fierro, Maria Fierro, M Marra, E Marra, Elena Quaglino, P Ribero, S Ribero, Simone Rubatto, M Rubatto, Marco Tonella, L Tonella, Luca
source	Medline; PMC
abstract	Melanoma epidemiology has shown a constant increase in the last few decades even if mortality is low and only a small percentage of patients develop metastatic disease. For these patients, immunotherapy with checkpoint inhibitors (ICI) significantly improves disease outcome with a median survival more than 2 years. The same drugs are used as adjuvant treatment in disease-free patients. Coronavirus Disease-19 (COVID-19) is now a pandemic disease with lung manifestations, which can bring severe acute respiratory distress. The most important risk factors related to a higher death risk for COVID-19 pneumonia are elderly age and comorbidities (hypertension, diabetes, previous cancer).
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1111/jdv.16586
bibo:pmid	32426877
has license	no-cc
sha1sum (hex)	6ad723f07ca82e62620f507c561b86a30e3e000c
schema:url	https://doi.org/10.1111/jdv.16586
resource representing a document's title	Metastatic melanoma treatment with checkpoint inhibitors in the COVID‐19 era: experience from an Italian Skin Cancer Unit
has PubMed Central identifier	PMC7276756
has PubMed identifier	32426877
schema:publication	J Eur Acad Dermatol Venereol
resource representing a document's body	covid:6ad723f07ca82e62620f507c561b86a30e3e000c#body_text
is schema:about of	named entity 'Lombardy' named entity 'IL-10' named entity 'metastatic disease' named entity 'ICI' named entity 'nivolumab' named entity 'comorbidities' named entity 'metastatic disease' named entity 'lost to follow-up' named entity 'MCP-1' named entity 'immune response' named entity 'metastatic disease' named entity 'adjuvant treatment' named entity 'COVID' named entity 'metastatic melanoma' named entity 'IL-7' named entity 'metastatic lung cancer' named entity 'ICI' named entity 'viral infections' named entity 'COVID' named entity 'disease-free' named entity 'COVID' named entity 'disease outcome' named entity 'follow-up' named entity 'disinfect' named entity 'COVID' named entity 'COVID-19' named entity 'pro-inflammatory cytokines' named entity 'COVID-19 infection' named entity 'infection' named entity 'virus' named entity 'nivolumab' named entity 'adjuvant treatment' named entity 'ICI' named entity 'immune mechanism' named entity 'G-CSF' named entity 'Th17' named entity 'pembrolizumab' named entity 'comorbidities' named entity 'Piedmont' named entity 'comorbidities' named entity 'Th1' named entity 'ICI' named entity 'elderly patients' named entity 'pneumonia' named entity 'comorbidities' named entity 'ipilimumab' named entity 'risk factors' named entity 'ICI' named entity 'differential diagnosis' named entity 'stage III' named entity 'critical situation' named entity 'checkpoint inhibitors' named entity 'metastatic melanoma' named entity 'hypertension' named entity 'pandemic disease' named entity 'adjuvant treatment' named entity 'viral pneumonia' named entity 'melanoma' named entity 'interferon' named entity 'toxicity' named entity 'acute respiratory distress' named entity 'Cutaneous' named entity 'lung' named entity 'ICI' named entity 'adverse events'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software